Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2 Results for "
Vevorisertib
" in MedChemExpress (MCE) Product Catalog:
Products (2)
2 Results for "Vevorisertib" in MCE Product Catalog:
2
Target:
Research Areas:
Vevorisertib (ARQ 751) is an orally active allosteric AKT inhibitor that blocks AKT phosphorylation. Vevorisertib inhibits tumor cell proliferation through Cyclin D1 and Ki67. Vevorisertib inhibits liver fibrosis through collagen accumulation, alpha-SMA, COL1, and TGF-beta. Vevorisertib reduces total bilirubin. Vevorisertib significantly reduces tumor size in a cirrhotic rat HCC model. Vevorisertib can be used for research on hepatocellular carcinoma .
2
2 Cited Publications
Synonyms: ARQ 751 trihydrochloride
Target:
Research Areas:
Vevorisertib trihydrochloride (ARQ 751 trihydrochloride) is an orally active allosteric AKT inhibitor that blocks AKT phosphorylation. Vevorisertib trihydrochloride inhibits tumor cell proliferation through Cyclin D1 and Ki67. Vevorisertib trihydrochloride inhibits liver fibrosis through collagen accumulation, alpha-SMA, COL1, and TGF-beta. Vevorisertib trihydrochloride reduces total bilirubin. Vevorisertib trihydrochloride significantly reduces tumor size in a cirrhotic rat HCC model. Vevorisertib trihydrochloride can be used for research on hepatocellular carcinoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
